A 59-year-old man with a history of metabolic dysfunction–associated steatotic liver disease had an enlarging liver mass. Biopsy showed hepatocellular carcinoma. Management decisions were made.

Given the success of Research Topic <a href=" in Chemotherapy-Resistant Hepatocellular Carcinoma and the rapidly evolving ...

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

This is called secondary liver cancer or liver metastases. Hepatocellular carcinoma is also called hepatoma or HCC. It's the most common type of primary liver cancer. Because of this, the information ...

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

With liver ailments on the rise, and obesity a key driver, understanding the treatment options available is critical.

The analysis included 16,501 participants: 3610 statin users and 12,891 nonusers. HealthDay News — For patients with chronic liver disease, statin use is associated with a reduced risk for ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver disease, according to findings in JAMA Internal Medicine. To examine ...

Statin users had a significantly lower 10-year cumulative incidence of hepatocellular carcinoma and hepatic decompensation.